Varubi
| Chemical Name | rolapitant |
| Dosage Form | Tablet (oral; 90 mg); injection (intravenous; 166.5 mg/92.5 mL) |
| Drug Class | Receptor antagonists |
| System | Digestive |
| Company | Tesaro Inc |
| Approval Year | 2015 |
Indication
- Indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.